The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Parkinson's disease
Open accessAbstract
Parkinson's disease is a recognisable clinical syndrome with a range of causes and clinical presentations. Parkinson's disease represents a fast-growing neurodegenerative condition; the rising prevalence worldwide resembles the many characteristics typically observed during a pandemic, except for an infectious cause. In most populations, 3-5% of Parkinson's disease is explained by genetic causes linked to known Parkinson's disease genes, thus representing monogenic Parkinson's disease, whereas 90 genetic risk variants collectively explain 16-36% of the heritable risk of non-monogenic Parkinson's disease. Additional causal associations include having a relative with Parkinson's disease or tremor, constipation, and being a non-smoker, each at least doubling the risk of Parkinson's disease. The diagnosis is clinically based; ancillary testing is reserved for people with an atypical presentation. Current criteria define Parkinson's disease as the presence of bradykinesia combined with either rest tremor, rigidity, or both. However, the clinical presentation is multifaceted and includes many non-motor symptoms. Prognostic counselling is guided by awareness of disease subtypes. Clinically manifest Parkinson's disease is preceded by a potentially long prodromal period. Presently, establishment of prodromal symptoms has no clinical implications other than symptom suppression, although recognition of prodromal parkinsonism will probably have consequences when disease-modifying treatments become available. Treatment goals vary from person to person, emphasising the need for personalised management. There is no reason to postpone symptomatic treatment in people developing disability due to Parkinson's disease. Levodopa is the most common medication used as first-line therapy. Optimal management should start at diagnosis and requires a multidisciplinary team approach, including a growing repertoire of non-pharmacological interventions. At present, no therapy can slow down or arrest the progression of Parkinson's disease, but informed by new insights in genetic causes and mechanisms of neuronal death, several promising strategies are being tested for disease-modifying potential. With the perspective of people with Parkinson's disease as a so-called red thread throughout this Seminar, we will show how personalised management of Parkinson's disease can be optimised.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Strikingly, non-motor symptoms remain poorly responsive to current PD treatments despite being present from early prodromal PD and contributing significantly to overall disease burden [36].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical practice guidelines support resilience training and exercise for patients with Parkinson’s disease (PD).”
From A randomized clinical trial of mindfulness meditation versus exercise in Parkinson’s disease during social unrest (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The diseases encompass various severe conditions, including neurodegenerative disorders like Alzheimer’s disease (AD) [3, 4] and Parkinson’s disease (PD) [5, 6], as well as traumatic brain injuries (TBI) [7] and spinal cord injuries (SCI) [8].”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Parkin and PINK1 mitigate STING-induced inflammation
Sliter, D. A., Martinez, J., Hao, L., Chen, X., Sun, N., Fischer, T. D., Burman, J. L., Li, Y., Zhang, Z., Narendra, D. P., et al. (2018) · Nature · doi:10.1038/s41586-018-0448-9 · Cited by 1,287
Self-citationRetractedStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Self-citationKalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Feigin, V. L., Nichols, E., Alam, T., Bannick, M. S., Beghi, E., Blake, N., Culpepper, W. J., Dorsey, E. R., Elbaz, A., Ellenbogen, R. G., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30499-x · Cited by 5,644
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
Huber, M., Knottnerus, J. A., Green, L., van der Horst, H. E., Jadad, A. R., Kromhout, D., Leonard, B. E., Lorig, K. R., Loureiro, I., Meer, J. W. M. V. D., et al. (2011) · BMJ · doi:10.1136/bmj.d4163 · Cited by 2,983
Diagnosis and Treatment of Parkinson Disease: A Review
Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924
Self-citationDorsey, E. R., Elbaz, A., Nichols, E., Abbasi, N., Abd-Allah, F., Abdelalim, A., Adsuar, J. C., Ansha, M. G., Brayne, C., Choi, J.-Y. J., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30295-3 · Cited by 2,816
Nalls, M. A., Blauwendraat, C., Vallerga, C. L., Heilbron, K., Bandres-Ciga, S., Chang, D., Tan, M., Kia, D. A., Noyce, A. J., Xue, A., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30320-5 · Cited by 2,454
Cited by
Sorted by citations
Items 201–300 of 1,004
Shen, L., Luo, Q., Hu, C.-B., Jiang, H., Yang, Y., Wang, G., Ji, Q., & Jia, Z. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.343892 · Cited by 50
Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research
Li, X., Liu, Q., Xie, X., Peng, C., Pang, Q., Liu, B., & Han, B. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01712 · Cited by 46
8-Hydroxyquinolylnitrones as multifunctional ligands for the therapy of neurodegenerative diseases
Knez, D., Diez‐Iriepa, D., Chioua, M., Gottinger, A., Denic, M., Chantegreil, F., Nachon, F., Brazzolotto, X., Skrzypczak-Wiercioch, A., Meden, A., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.01.013 · Cited by 46
SARS‐COV‐2 infection and Parkinson's disease: Possible links and perspectives
Al-Kuraishy, H. M., Al-Gareeb, A. I., Kaushik, A. K., Kujawska, M., Ahmed, E., & Batiha, G. E. (2023) · Journal of Neuroscience Research · doi:10.1002/jnr.25171 · Cited by 47
Youssef, P., Hughes, L., Kim, W. S., Halliday, G. M., Lewis, S. J. G., Cooper, A., & Dzamko, N. (2023) · Scientific Reports · doi:10.1038/s41598-023-32480-0 · Cited by 46
Wang, S., Zhu, G., Shi, L., Zhang, C., Wu, B., Yang, A., Meng, F., Jiang, Y., & Zhang, J. (2023) · Journal of Parkinson s Disease · doi:10.3233/jpd-225053 · Cited by 52
Advances in Zebrafish as a Comprehensive Model of Mental Disorders
Wang, L., Liu, F., Fang, Y., Ma, J., Wang, J., Qu, L., Yang, Q., Wu, W., Jin, L., & Sun, D. (2023) · Depression and Anxiety · doi:10.1155/2023/6663141 · Cited by 52
Macrophage‐Biomimetic Nanoplatform‐Based Therapy for Inflammation‐Associated Diseases
Qu, Y., Chu, B., Li, J., Deng, H., Niu, T., & Qian, Z. (2023) · Small Methods · doi:10.1002/smtd.202301178 · Cited by 46
Zhong, G., Wang, X., Li, J., Xie, Z., Wu, Q., Chen, J., Wang, Y., Chen, Z., Cao, X., Li, T., et al. (2023) · Current Neuropharmacology · doi:10.2174/1570159x22666231103085859 · Cited by 49
Advances in animal models of Parkinson's disease
He, S., Ru, Q., Chen, L., Xu, G., & Wu, Y. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.111024 · Cited by 54
Ebadpour, N., Mahmoudi, M., Kheder, R. K., Abavisani, M., Baridjavadi, Z., Abdollahi, N., & Esmaeili, S. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113015 · Cited by 48
Pulling back the mitochondria’s iron curtain
David, S. B. Z., Shkuri, L., & Ast, T. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00045-y · Cited by 59
Fołta, J., Rzepka, Z., & Wrześniok, D. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115177 · Cited by 50
From blood to brain: blood cell-based biomimetic drug delivery systems
Li, Y., Wu, J., Liu, J., Qiu, X., Xu, W., Tang, T., & Xiang, D. (2021) · Drug Delivery · doi:10.1080/10717544.2021.1937384 · Cited by 46
Gomes, L. C., Galhoz, A., Jain, G., Roser, A., Maass, F., Carboni, E., Barski, E., Lenz, C., Lohmann, K., Klein, C., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.692 · Cited by 46
Self-citationBouça‐Machado, R., Fernandes, A. B., Ranzato, C., Beneby, D., Nzwalo, H., & Ferreira, J. J. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.945398 · Cited by 45
An Apple a Day to Keep the Parkinson's Disease Doctor Away?
Bloem, B. R., Post, E., & Hall, D. A. (2023) · Annals of Neurology · doi:10.1002/ana.26612 · Cited by 45
Self-citationAggregation-induced emission: An illuminator in the brain
Duo, Y., Yang, Y., Xu, T., Zhou, R., Wang, R., Luo, G., & Tang, B. Z. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215070 · Cited by 44
Identification of Parkinson's Disease Subtypes from Resting‐State Electroencephalography
Yassine, S., Gschwandtner, U., Auffret, M., Duprez, J., Vérin, M., Fuhr, P., & Hassan, M. (2023) · Movement Disorders · doi:10.1002/mds.29451 · Cited by 45
Yang, K., Zeng, L., Zeng, J., Deng, Y., Wang, S., Xu, H., He, Q., Yuan, M., Luo, Y., Ge, A., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102063 · Cited by 46
Slézia, A., Hegedüs, P., Rusina, E., Lengyel, K., Solari, N., Kaszás, A., Balázsfi, D., Botzanowski, B., Acerbo, E., Missey, F., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-46576-0 · Cited by 48
Taxak, B., Devi, J., Dubey, A., Kumar, B., Tufail, A., Pachwania, S., & Boora, A. (2023) · Applied Organometallic Chemistry · doi:10.1002/aoc.7323 · Cited by 45
Ibrahim, A. M., & Mohammed, M. A. (2024) · International Journal of Mathematics Statistics and Computer Science · doi:10.59543/ijmscs.v2i.8915 · Cited by 45
Alpha-Synuclein and Microglia in Parkinson’s Disease: From Pathogenesis to Therapeutic Prospects
Eo, H., Kim, S., Jung, U. J., & Kim, S. R. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237243 · Cited by 47
Parkinson's disease and glucose metabolism impairment
Chen, L., Wang, C., Qin, L., & Zhang, H. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00467-8 · Cited by 51
Kwok, J. Y. Y., Choi, E. P. H., Wong, J. Y. H., Lok, K. Y. W., Ho, M.-H., Fong, D. Y. T., Kwan, J. C. Y., Pang, S. Y. Y., & Auyeung, M. (2023) · npj Parkinson's Disease · doi:10.1038/s41531-023-00452-w · Cited by 43
Wang, W., Lv, Z., Gao, J., Liu, M., Wang, Y., Tang, C., & Xiang, J. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.06.024 · Cited by 44
Li, Q., Wu, C., Wang, X., Li, Z., Hao, X., Zhao, L., Li, M., & Zhu, M. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.995850 · Cited by 44
Wu, P., Cao, B., Liang, Z., & Wu, M. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1191378 · Cited by 47
Vrettou, S., & Wirth, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415849 · Cited by 45
Patterson, C. G., Joslin, E., Gil, A. B., Spigle, W. A., Nemet, T., Chahine, L. M., Christiansen, C. L., Melanson, E., Kohrt, W. M., Mancini, M., et al. (2022) · Trials · doi:10.1186/s13063-022-06703-0 · Cited by 48
Lu, C., Qu, S., Zhong, Z., Luo, H., Lei, S. S., Zhong, H., Su, H., Wang, Y., & Chong, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.963327 · Cited by 43
Behavioral encoding across timescales by region-specific dopamine dynamics
Jørgensen, S. H., Ejdrup, A. L., Lycas, M. D., Posselt, L. P., Madsen, K. L., Tian, L., Dreyer, J. K., Herborg, F., Sørensen, A. T., & Gether, U. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2215230120 · Cited by 44
Nakmode, D. D., Day, C. M., Song, Y., & Garg, S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051503 · Cited by 48
Brain Dynamics Complexity as a Signature of Cognitive Decline in Parkinson's Disease
Fiorenzato, E., Moaveninejad, S., Weis, L., Biundo, R., Antonini, A., & Porcaro, C. (2023) · Movement Disorders · doi:10.1002/mds.29678 · Cited by 43
Airy-beam holographic sonogenetics for advancing neuromodulation precision and flexibility
Hu, Z., Yang, Y., Yang, L., Gong, Y., Chukwu, C., Ye, D., Yue, Y., Yuan, J., Kravitz, A. V., & Chen, H. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2402200121 · Cited by 42
Updated MDSGene review on the clinical and genetic spectrum of LRRK2 variants in Parkinson´s disease
Krüger, C., Lim, S., Buhrmann, A., Fahrig, F. L., Gabbert, C., Bahr, N., Madoev, H., Marras, C., Klein, C., & Lohmann, K. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00881-9 · Cited by 45
Self-citationMoving, fast and slow: behavioural insights into bradykinesia in Parkinson’s disease
Herz, D. M., & Brown, P. (2023) · Brain · doi:10.1093/brain/awad069 · Cited by 53
Debelle, H., Packer, E., Beales, E., Bailey, H. G. B., Ardle, R. M., Brown, P. M., Hunter, H., Ciravegna, F., Ireson, N., Evers, J., et al. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1111260 · Cited by 42
Zeng, Q., Liu, P., Yu, N., Wu, J., Huo, W., & Han, J. (2023) · IEEE Transactions on Neural Systems and Rehabilitation Engineering · doi:10.1109/tnsre.2023.3291359 · Cited by 43
Wang, J., Zhao, L., & Yan, B. (2021) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2021.131297 · Cited by 42
ATP and NAD+ Deficiency in Parkinson’s Disease
Mischley, L. K., Shankland, E. G., Liu, S. Z., Bhayana, S., Fox, D. J., & Marcinek, D. J. (2023) · Nutrients · doi:10.3390/nu15040943 · Cited by 41
Recent updates on structural insights of MAO-B inhibitors: a review on target-based approach
Baweja, G. S., Gupta, S., Kumar, B., Patel, P., & Asati, V. (2023) · Molecular Diversity · doi:10.1007/s11030-023-10634-6 · Cited by 44
Role of piRNA biogenesis and its neuronal function in the development of neurodegenerative diseases
Sato, K., Takayama, K.-I., & Inoue, S. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1157818 · Cited by 41
Rodger, A. T., ALNasser, M. N., & Carter, W. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311022 · Cited by 41
A novel NIR fluorescent probe for copper( ii ) imaging in Parkinson's disease mouse brain
Chen, J., Luo, R., Li, S., Shao, J., Wang, T., Xie, S., Xu, L., You, Q., Feng, S., & Feng, G. (2024) · Chemical Science · doi:10.1039/d4sc03445g · Cited by 42
Inflammasomes in neurodegenerative diseases
Wang, Q., Yang, S., Zhang, X., Zhang, S., Chen, L., Wang, W., Chen, N., & Yan, J. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00459-0 · Cited by 47
Vitamin D Status and Parkinson’s Disease
Barichella, M., Garrì, F., Caronni, S., Bolliri, C., Zocchi, L., Macchione, M. C., Ferri, V., Calandrella, D., & Pezzoli, G. (2022) · Brain Sciences · doi:10.3390/brainsci12060790 · Cited by 45
Effect Modification between Genes and Environment and Parkinson's Disease Risk
Periñán, M. T., Brolin, K. A., Bandrés‐Ciga, S., Blauwendraat, C., Klein, C., Gan‐Or, Z., Singleton, A., Gómez‐Garre, P., Swanberg, M., Mir, P., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26467 · Cited by 41
Self-citationPharmacological PINK1 activation ameliorates Pathology in Parkinson’s Disease modelsPreprint
Chin, R., Rakhit, R., Ditsworth, D., Wang, C., Bartholoméüs, J., Liu, S., Mody, A., Laishu, A., Eastes, A., Tai, C., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.14.528378 · Cited by 42
Wang, X., Feng, S., Wang, Y., Zhang, N., Guo, Z., Xu, Y., Yuan, Y., Wang, Z., Chen, N., & Zhang, Y. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154281 · Cited by 40
Jiang, X., Wu, K., Ye, X., Xie, T., Zhang, P., Blass, B. E., & Bai, R. (2023) · Medicinal Research Reviews · doi:10.1002/med.21939 · Cited by 40
Plachokova, A. S., Gjaltema, J., Hagens, E., Hashemi, Z., Knüppe, T., Kootstra, T. J. M., Visser, A., & Bloem, B. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084504 · Cited by 45
Self-citationHatzimanolis, O., Sykes, A. M., & Cristino, A. S. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02925-1 · Cited by 44
Recent advances in functional lipid-based nanomedicines as drug carriers for organ-specific delivery
Yun, Y., An, J., Kim, H. J., Choi, H. K., & Cho, H. (2025) · Nanoscale · doi:10.1039/d4nr04778h · Cited by 45
Mitophagy in Neurons: Mechanisms Regulating Mitochondrial Turnover and Neuronal Homeostasis
Basak, B., & Holzbaur, E. L. F. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169161 · Cited by 44
Soluble Epoxide Hydrolase as a Therapeutic Target for Neuropsychiatric Disorders
Shan, J., & Hashimoto, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094951 · Cited by 41
A Hybrid U-Lossian Deep Learning Network for Screening and Evaluating Parkinson’s Disease
Maskeliūnas, R., Damaševičius, R., Kulikajevas, A., Padervinskis, E., Pribuišis, K., & Uloza, V. (2022) · Applied Sciences · doi:10.3390/app122211601 · Cited by 40
New Understanding on the Pathophysiology and Treatment of Constipation in Parkinson’s Disease
Xu, J., Wang, L., Chen, X., & Le, W. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.917499 · Cited by 41
Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease
Luca, D. G. D., Reyes, N. G. D., & Fox, S. H. (2022) · Drugs · doi:10.1007/s40265-022-01747-7 · Cited by 39
Mishra, J., Bhatti, G. K., Sehrawat, A., Singh, C., Singh, A., Reddy, A. P., Reddy, P. H., & Bhatti, J. S. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121153 · Cited by 38
Winchester, L. M., Barber, I., Lawton, M., Ash, J. A., Liu, B., Evetts, S. G., Hopkins‐Jones, L., Lewis, S., Bresner, C., Malpartida, A. B., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac343 · Cited by 39
Rigidity in Parkinson’s disease: evidence from biomechanical and neurophysiological measures
Asci, F., Falletti, M., Zampogna, A., Patera, M., Hallett, M., Rothwell, J. C., & Suppa, A. (2023) · Brain · doi:10.1093/brain/awad114 · Cited by 39
Leyns, C. E. G., Prigent, A., Beezhold, B., Yao, L., Hatcher, N. G., Tao, P., Kang, J. J., Suh, E. R., Deerlin, V. M. V., Trojanowski, J. Q., et al. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00517-w · Cited by 38
Liu, L.-L., Han, Y., Zhang, Z., Wang, Y., Hu, Y., Kaznacheyeva, E. V., Ding, J., Guo, D., Wang, G., Li, B., et al. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01104-8 · Cited by 39
Hou, Y., Ji, J., Zhu, Y. S., Dell, T., & Liu, X. (2023) · IEEE Transactions on Biomedical Circuits and Systems · doi:10.1109/tbcas.2023.3281596 · Cited by 39
Meng, F.-G., Hu, W., Wang, S., Tam, J., Gao, Y., Zhu, X., Chan, D. T., Poon, W.-S., Poon, T., Cheung, F.-C., et al. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000603 · Cited by 34
Intelligent Identification of Cerebrospinal Fluid for the Diagnosis of Parkinson’s Disease
Chen, H., Guo, S., Zhuang, Z., Ouyang, S., Lin, P., Zheng, Z., You, Y., Zhou, X. Y., Li, Y., Lu, J., et al. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.3c04849 · Cited by 39
Quan, P., Li, X., Si, Y., Sun, L., Ding, F. F., Fan, Y., Liu, H., Wei, C., Li, R., Zhao, X. L., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01590-1 · Cited by 43
Altham, C., Zhang, H., & Pereira, E. (2024) · PLoS ONE · doi:10.1371/journal.pone.0303644 · Cited by 46
Bernstein, H., Nussbaumer, M., Vasilevska, V., Dobrowolny, H., Nickl‐Jockschat, T., Guest, P. C., & Steiner, J. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02861-6 · Cited by 42
Zhao, R., Tian, X., Xu, H., Wang, Y., Lin, J., & Wang, B. (2025) · Aging Cell · doi:10.1111/acel.70061 · Cited by 42
Avagliano, C., Coretti, L., Lama, A., Pirozzi, C., Caro, C. D., Biase, D. D., Turco, L., Mollica, M. P., Paciello, O., Calignano, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126367 · Cited by 41
DNA Damage-Mediated Neurotoxicity in Parkinson’s Disease
Wang, Z., Li, Y., Pu, J., & Zhang, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076313 · Cited by 43
Cognitive Impact of Deep Brain Stimulation in Parkinson’s Disease Patients: A Systematic Review
Rački, V., Hero, M., Rožmarić, G., Papić, E., Raguž, M., Chudy, D., & Vuletić, V. (2022) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2022.867055 · Cited by 38
Scuto, M. C., Modafferi, S., Rampulla, F., Zimbone, V., Tomasello, M., Spanò, S. M., Ontario, M. L., Palmeri, A., Salinaro, A. T., Siracusa, R., et al. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2022.111686 · Cited by 40
Szarowicz, C. A., Steece‐Collier, K., & Caulfield, M. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23148011 · Cited by 43
Elmorsy, E. M., Al-Ghafari, A. B., Doghaither, H. A. A., Salama, M., & Carter, W. G. (2022) · Brain Sciences · doi:10.3390/brainsci12080975 · Cited by 39
Xu, R.-C., Miao, W.-T., Xu, J., Xu, W. V., Liu, M.-R., Ding, S., Jian, Y.-X., Lei, Y.-H., Yan, N., & Liu, H.-D. (2022) · Nutrients · doi:10.3390/nu14194163 · Cited by 41
Torrado, J. C., Husebo, B. S., Allore, H. G., Erdal, A., Fæø, S. E., Reithe, H., Førsund, E., Tzoulis, C., & Pătraşcu, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275747 · Cited by 38
Huang, L., Zhou, Y., Jiao, D., Ren, J., Qi, Y., Wang, H., Shi, Y., Ding, D., & Xue, X. (2023) · Aggregate · doi:10.1002/agt2.403 · Cited by 38
PTBP1 as a potential regulator of disease
Yu, Q., Wu, T., Xu, W., Wei, J., Zhao, A., Wang, M., Li, M., & Chi, G. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04905-x · Cited by 41
Guan, Y., Tang, G., Li, L., Shu, J., Zhao, Y., Huang, L., & Tang, J. (2024) · Archives of Pharmacal Research · doi:10.1007/s12272-023-01484-9 · Cited by 41
Yaribash, S., Mohammadi, K., & Sani, M. A. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01544-2 · Cited by 44
Lim, J. L., Lohmann, K., Tan, A. H., Tay, Y. W., Ibrahim, K. A., Aziz, Z. A., Mawardi, A. S., Puvanarajah, S. D., Lim, T. T., Looi, I., et al. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02421-0 · Cited by 36
Self-citationHabets, J., Herff, C., Kubben, P., Kuijf, M. L., Temel, Y., Evers, L. J. W., Bloem, B. R., Starr, P. A., Gilron, R., & Little, S. J. (2021) · Sensors · doi:10.3390/s21237876 · Cited by 40
Self-citationThe Chinese Parkinson's Disease Registry ( CPDR ): Study Design and Baseline Patient Characteristics
Zhou, X., Liu, Z., Zhou, X., Xiang, Y., Zhou, Z., Zhao, Y., Pan, H., Xu, Q., Chen, Y., Sun, Q., et al. (2022) · Movement Disorders · doi:10.1002/mds.29037 · Cited by 39
Guo, M., Ji, X., & Liu, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.919343 · Cited by 40
Cheng, G., Li, Z., Liu, Y., Ma, R., Chen, X., Liu, W., Song, Y., Zhang, Y., Yu, G., Wu, Z., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.024 · Cited by 37
The toxic metal hypothesis for neurological disorders
Pamphlett, R., & Bishop, D. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1173779 · Cited by 44
Chen, H., Dunk, M. M., Wang, B., Zhao, M., Shen, J., Zong, G., Pan, Y., Tong, L., Xu, W., & Yuan, C. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13521 · Cited by 36
Strategies targeting endoplasmic reticulum stress to improve Parkinson’s disease
Wang, D., Qu, S., Zhang, Z., Tan, L., Chen, X., Zhong, H., & Chong, C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1288894 · Cited by 40
Rosh, I., Tripathi, U., Hussein, Y., Rike, W. A., Djamus, J., Shklyar, B., Manole, A., Houlden, H., Winkler, J., Gage, F. H., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00653-x · Cited by 41
Mohan, M., Mannan, A., Kakkar, C., & Singh, T. G. (2024) · Current Drug Targets · doi:10.2174/0113894501320839240918110656 · Cited by 37
Jeon, J., Cha, Y., Hong, Y. J., Lee, I., Jang, H., Ko, S., Naumenko, S., Kim, M., Ryu, H. L., Shrestha, Z., et al. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.01.006 · Cited by 40
Validity and Prognostic Value of a Polygenic Risk Score for Parkinson’s Disease
Sendel, S., Laabs, B., Kasten, M., Vollstedt, E., Becktepe, J. S., Brüggemann, N., Franke, A., Krämer, U. M., Kuhlenbäumer, G., Lieb, W., et al. (2021) · Genes · doi:10.3390/genes12121859 · Cited by 38
Self-citationLiu, C., Liu, Z., Fang, Y., Du, Z., Yan, Z., Yuan, X., Dai, L., Yu, T., Xiong, M., Tian, Y., et al. (2022) · Chemosphere · doi:10.1016/j.chemosphere.2022.136344 · Cited by 37
Chen, F., Chen, S., Si, A., Luo, Y., Hu, W., Zhang, Y., & Ma, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.973310 · Cited by 37
Pelowski, M. J., Spee, B. T. M., Arató, J., Dörflinger, F., Ishizu, T., & Richard, A. (2022) · Physics of Life Reviews · doi:10.1016/j.plrev.2022.07.005 · Cited by 38
RetractedGolgi-targeted fluorescent probe for nitric oxide imaging in Parkinson’s disease models
Zheng, Z., Gong, S., Zhang, J., Liu, Y., & Feng, G. (2023) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2023.134654 · Cited by 37
Metadata
- Authors
- Bloem, B. R., Okun, M. S., & Klein, C.
- Affiliations
- Radboud University Nijmegen (NL)
- University of Florida Health (US)
- University Hospital Schleswig-Holstein (DE)
- Corresponding author
- Bloem, Bastiaan R
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-06
- Volume
- 397
- Issue
- 10291
- Pages
- 2284-2303
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4206481149
- Cited by
- 3,920
- References
- 159
- Citations by year
- 2026: 878 · 2025: 1098 · 2024: 901 · 2023: 607 · 2022: 364 · 2021: 72
- FWCI
- 62.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- Deutsche Forschungsgemeinschaft
- Parkinson's Foundation (FOR2488)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, neurodegeneration, genetic risk variants, monogenic Parkinson's disease, non-motor symptoms, levodopa, disease-modifying therapy, multidisciplinary care, non-pharmacological treatment, diagnosis, prodromal period
- MeSH terms
- Antiparkinson Agents, Humans, Levodopa, Parkinson Disease, Time Factors, Tremor, Disease Management, Prodromal Symptoms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
